CoChat

Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern

Open access
Kim, Hyoung Woo, Lee, Jong-chan, Paik, Kyu-hyun, Kang, Jingu, Kim, Jaihwan, Hwang, Jin-Hyeok · 2017 · Medicine

The DOI matches its Crossref record; 24 of the 27 references it cites were found in a registry or an index.

Abstract

Several reports showed that interleukin-6 (IL-6) or -8 (IL-8) might be useful inflammatory biomarkers for pancreatic ductal adenocarcinoma (PDAC), although these clinical impact is still open to debate. The aim of this study was to elucidate whether serum levels of IL-6 and IL-8 at diagnosis could predict the tumor progression pattern of PDAC, especially in extensive hepatic metastasis.According to the tumor burden of hepatic metastasis at the last follow-up, tumor progression pattern was defined as follows: no or limited (unilobar involvement and 5 or less in the within liver, limited group) and extensive hepatic metastasis (bilobar or more than 5, progressed group). Fifty-three PDAC patients with initially no or limited hepatic metastasis were enrolled retrospectively.Around 42 (79.2%) were included in the limited and 11 (20.8%) in the progressed group. The median serum level of IL-6 in the progressed group was elevated significantly compared with the limited group. However, the median serum level of IL-8 was not. Furthermore, multivariate analysis revealed that the elevated serum level of IL-6 was an independent risk factor for progression to extensive hepatic metastasis (odds ratio 1.928, 95% confidence interval 1.131-3.365, P = 0.019), but IL-8 was not. However, higher IL-6 did not predict shorter survival.High serum IL-6 can be an independent risk factor for progression to extensive hepatic metastasis in PDAC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000005926

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) The serum level of the Ln IL-6 in the limited and progressed group. The median serum level of Ln IL-6 of the progressed group was significantly greater than that of the limited group (2.0 vs 1.4, P = 0.025). (B) The serum level of the Ln IL-8 in the limited and progressed group. There was no significant correlation between the median serum level of Ln IL-8 and the tumor progression pattern (3.2 vs 3.5, P = 0.978). Ln = natural logarithm.
Figure 1 (A) The serum level of the Ln IL-6 in the limited and progressed group. The median serum level of Ln IL-6 of the progressed group was significantly greater than that of the limited group (2.0 vs 1.4, P = 0.025). (B) The serum level of the Ln IL-8 in the limited and progressed group. There was no significant correlation between the median serum level of Ln IL-8 and the tumor progression pattern (3.2 vs 3.5, P = 0.978). Ln = natural logarithm.CC BY-ND · PubMed Central
Figure 2 (A) The correlation between the serum level of Ln IL-6 and CRP. (B) The correlation between the serum level of Ln IL-6 and NLR. (C) The correlation between the serum level of Ln IL-8 and CRP. (D) The correlation between the serum level of Ln IL-8 and NLR. Ln = natural logarithm, IL = interleukin, CRP = C-reactive protein, NLR = neutrophil-lymphocyte ratio.
Figure 2 (A) The correlation between the serum level of Ln IL-6 and CRP. (B) The correlation between the serum level of Ln IL-6 and NLR. (C) The correlation between the serum level of Ln IL-8 and CRP. (D) The correlation between the serum level of Ln IL-8 and NLR. Ln = natural logarithm, IL = interleukin, CRP = C-reactive protein, NLR = neutrophil-lymphocyte ratio.CC BY-ND · PubMed Central
Figure 3 (A) Kaplan–Meier analysis of overall survival according to the median serum values of Ln IL-6. (B) Kaplan–Meier analysis of overall survival according to the median serum values of Ln IL-8. Ln = natural logarithm, IL = interleukin.
Figure 3 (A) Kaplan–Meier analysis of overall survival according to the median serum values of Ln IL-6. (B) Kaplan–Meier analysis of overall survival according to the median serum values of Ln IL-8. Ln = natural logarithm, IL = interleukin.CC BY-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 53

Metadata

Authors
Kim, H. W., Lee, J.-C., Paik, K.-H., Kang, J., Kim, J., & Hwang, J.-H.
Affiliations
Seoul National University (KR)
Corresponding author
Hwang, Jin-Hyeok
Venue
Medicine
Published
2017-02
Volume
96
Issue
5
Pages
e5926
ISSN
0025-7974 (ISSN-L)
OpenAlex
W2617028083
Cited by
52
References
27
Citations by year
2025: 5 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 1
FWCI
2.41
Type
journal article
Language
en
Open access
Licence
cc-by-nd
Locations
  • Medicine (publishedVersion, cc-by-nd)
  • PubMed Central (publishedVersion, cc-by-nd)
  • PubMed (publishedVersion)
Funders
  • Seoul National University Bundang Hospital
  • Seoul National University
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
pancreatic ductal adenocarcinoma, interleukin-6, interleukin-8, serum biomarkers, liver metastasis, tumor progression, inflammatory markers, prognostic factors, survival
MeSH terms
Aged, Female, Humans, Liver Neoplasms, Male, Middle Aged, Pancreatic Neoplasms, Prognosis, Retrospective Studies, Risk Factors, Biomarkers, Tumor, Interleukin-6, Interleukin-8, Disease Progression, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. https://app.cochat.ai/papers/10.1097/md.0000000000005926
The paper
Kim, H. W., Lee, J.-C., Paik, K.-H., Kang, J., Kim, J., & Hwang, J.-H. (2017). Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine. https://doi.org/10.1097/md.0000000000005926

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.